Concerns mount among Korean drug makers

Published: 2007-10-02 07:00:00

Updated: 2007-10-02 07:00:00

The domestic pharmaceutical sector is expected to face an inevitable blow following the government's recent decision that Daewon Pharm's new oral medication Peluvi (felubiprofen) is not reimbursable.

The Health Insurance Review Agent said on September 20 that it could not accept the insurance ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK